(NASDAQ: NEUP) Neuphoria Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.
Neuphoria Therapeutics's earnings in 2025 is -$241,589.On average, 5 Wall Street analysts forecast NEUP's earnings for 2026 to be -$9,667,156, with the lowest NEUP earnings forecast at -$16,866,363, and the highest NEUP earnings forecast at -$4,703,438. On average, 5 Wall Street analysts forecast NEUP's earnings for 2027 to be -$7,326,518, with the lowest NEUP earnings forecast at -$13,400,672, and the highest NEUP earnings forecast at -$2,995,347.
In 2028, NEUP is forecast to generate -$7,346,558 in earnings, with the lowest earnings forecast at -$10,974,689 and the highest earnings forecast at -$3,366,671.